Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Chronic Pain-Pipeline Review, H1 2015

Chronic Pain-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Chronic Pain-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chronic Pain-Pipeline Review, H1 2015', provides an overview of the Chronic Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Pain

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chronic Pain and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chronic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chronic Pain pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chronic Pain

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 10

Introduction 11

Global Markets Direct Report Coverage 11

Chronic Pain Overview 12

Therapeutics Development 13

Pipeline Products for Chronic Pain-Overview 13

Pipeline Products for Chronic Pain-Comparative Analysis 14

Chronic Pain-Therapeutics under Development by Companies 15

Chronic Pain-Therapeutics under Investigation by Universities/Institutes 22

Chronic Pain-Pipeline Products Glance 23

Late Stage Products 23

Clinical Stage Products 24

Early Stage Products 25

Unknown Stage Products 26

Chronic Pain-Products under Development by Companies 27

Chronic Pain-Products under Investigation by Universities/Institutes 35

Chronic Pain-Companies Involved in Therapeutics Development 36

AbbVie Inc. 36

Acadia Pharmaceuticals Inc. 37

Adynxx, Inc. 38

Akron Molecules AG 39

Allergan, Inc. 40

arGEN-X BV 41

Astellas Pharma Inc. 42

Astraea Therapeutics, LLC 43

AstraZeneca PLC 44

BCN Peptides, S.A. 45

BioDelivery Sciences International, Inc. 46

Bionomics Limited 47

Cara Therapeutics, Inc. 48

ChironWells GmbH 49

Chromocell Corporation 50

Collegium Pharmaceutical, Inc. 51

CoLucid Pharmaceuticals, Inc. 52

Convergence Pharmaceuticals Ltd. 53

Creabilis SA 54

Cytogel Pharma, LLC 55

Daewoong Pharmaceutical Co., Ltd. 56

Daiichi Sankyo Company, Limited 57

Dompe Farmaceutici S.p.A. 58

DURECT Corporation 59

Egalet Corporation 60

Eli Lilly and Company 61

Endo Pharmaceuticals Inc. 62

Glenmark Pharmaceuticals Ltd. 63

Grunenthal GmbH 64

Johnson & Johnson 65

Kareus Therapeutics, SA 66

Kineta, Inc. 67

Kymab Limited 68

Laboratorios Del Dr. Esteve S.A. 69

Lohocla Research Corporation 70

Merck & Co., Inc. 71

Mertiva AB 72

Mesoblast Limited 73

Moberg Pharma AB 74

Mundipharma International Limited 75

Nanomerics Ltd 76

Nektar Therapeutics 77

Neura Therapeutik, LLC 78

Nippon Shinyaku Co., Ltd. 79

Orion Oyj 80

Pain Therapeutics, Inc. 81

Pfizer Inc. 82

Phosphagenics Limited 83

Purdue Pharma L.P. 84

Relmada Therapeutics, Inc. 85

Rottapharm SpA 86

Santen Pharmaceutical Co., Ltd. 87

Sea4Us 88

Shionogi & Co., Ltd. 89

Signature Therapeutics, Inc 90

Snowdon Inc. 91

Syntrix Biosystems, Inc. 92

Teikoku Pharma USA, Inc. 93

Teva Pharmaceutical Industries Limited 94

Trevena, Inc. 95

UMeWorld Limited 96

Zynerba Pharmaceuticals, Inc. 97

Chronic Pain-Therapeutics Assessment 98

Assessment by Monotherapy Products 98

Assessment by Combination Products 99

Assessment by Target 100

Assessment by Mechanism of Action 104

Assessment by Route of Administration 108

Assessment by Molecule Type 110

Drug Profiles 112

(celecoxib + tramadol hydrochloride)-Drug Profile 112

(oxycodone hydrochloride + naltrexone) ER-Drug Profile 113

A-836339-Drug Profile 115

AAT-008-Drug Profile 116

AGN-XX/YY-Drug Profile 117

AKR-201-Drug Profile 118

APR-102-Drug Profile 119

ARX-8203-Drug Profile 120

ASP-7962-Drug Profile 122

AXS-01-Drug Profile 123

AXS-03-Drug Profile 124

AYX-1-Drug Profile 125

AYX-2-Drug Profile 126

BBI-11008-Drug Profile 127

bupivacaine hydrochloride-Drug Profile 128

buprenorphine hydrochloride-Drug Profile 130

buprenorphine hydrochloride depot-Drug Profile 132

buprenorphine hydrochloride ER-Drug Profile 133

cebranopadol-Drug Profile 134

celecoxib-Drug Profile 136

CNV-3000164-Drug Profile 138

CNV-3000223-Drug Profile 139

Conjugated Stigmine Program-Drug Profile 140

CR-701-Drug Profile 141

CR-845-Drug Profile 142

CRB-0022-Drug Profile 144

CRB-0089-Drug Profile 145

CT-340-Drug Profile 146

Cyt-1010-Drug Profile 147

DD-04107-Drug Profile 149

dexmedetomidine hydrochloride-Drug Profile 150

DF-2593A-Drug Profile 152

Drugs for Chronic Pain and Inflammation-Drug Profile 153

Drugs for Chronic Pelvic Pain-Drug Profile 154

DS-1971-Drug Profile 155

duloxetine hydrochloride DR-Drug Profile 156

DWJ-208-Drug Profile 158

E-52862-Drug Profile 159

Egalet-003-Drug Profile 161

flurbiprofen-Drug Profile 162

FY-101C-Drug Profile 163

FY-103B-Drug Profile 164

GBR-900-Drug Profile 165

Gene Therapy to Activate Endomorphin 2 for Chronic Pain-Drug Profile 166

Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain-Drug Profile 167

GIBH-1014-Drug Profile 168

grapiprant-Drug Profile 169

HS-731-Drug Profile 171

hydrocodone bitartrate-Drug Profile 172

hydrocodone bitartrate ER-Drug Profile 173

hydrocodone bitartrate ER-Drug Profile 175

hydrocodone bitartrate ER-Drug Profile 176

hydromorphone hydrochloride-Drug Profile 177

Kindolor-Drug Profile 178

KY-1017-Drug Profile 180

LEVI-04-Drug Profile 181

levorphanol tartrate ER-Drug Profile 182

lexanopadol-Drug Profile 183

mirogabalin-Drug Profile 184

Monoclonal Antibodies for Chronic Pain-Drug Profile 186

Monoclonal Antibodies to Block Nav1.7 for Chronic Pain-Drug Profile 187

morphine sulfate ER-Drug Profile 188

MPC-06ID-Drug Profile 189

NET-END-Drug Profile 191

NKTR-181-Drug Profile 192

NL-001-Drug Profile 194

NL-002-Drug Profile 195

NM-0127-Drug Profile 196

Omnitram-Drug Profile 197

onabotulinumtoxin A-Drug Profile 198

OSX-300-Drug Profile 200

OSX-300 Backups-Drug Profile 201

oxycodone ER-Drug Profile 202

oxycodone hydrochloride ER-Drug Profile 204

oxycodone hydrochloride ER-Drug Profile 206

oxycodone hydrochloride ER-Drug Profile 207

oxycodone hydrochloride ER-Drug Profile 208

oxymorphone hydrochloride-Drug Profile 210

oxymorphone hydrochloride ER-Drug Profile 211

palmidrol-Drug Profile 212

Peptide to Block Calcium Channel for CNS Disorders-Drug Profile 213

Peptides to Inhibit Ion Channel for Chronic Pain-Drug Profile 214

PF-05089771-Drug Profile 215

PF-06372865-Drug Profile 217

PF-329-Drug Profile 218

PF-6129-Drug Profile 219

PF-614-Drug Profile 220

PFR-03088-Drug Profile 221

PFR-03318-Drug Profile 222

PFR-03321-Drug Profile 223

PFR-03323-Drug Profile 224

PFR-03325-Drug Profile 225

PFR-06158-Drug Profile 226

PFR-06177-Drug Profile 227

PRC-062-Drug Profile 228

Prostatic Acid Phosphatase-Drug Profile 229

PTI-202-Drug Profile 230

PTI-721-Drug Profile 232

SA-14867-Drug Profile 233

Small Molecule Agonizing ER-Beta for Neurology and Pain-Drug Profile 234

Small Molecule for Central Nervous System-Drug Profile 235

Small Molecule for Chronic Pain-Drug Profile 237

Small Molecule for Neuropathic Pain and Inflammatory Pain-Drug Profile 238

Small Molecule to Agonize mGlu2/3 for Chronic Pain-Drug Profile 239

Small Molecule to Antagonize TRPA1 for Chronic Pain-Drug Profile 240

Small Molecule to Block Cav2.2 Channel for Chronic Pain-Drug Profile 241

Small Molecule to Inhibit ASK-1 for Chronic Pain-Drug Profile 242

Small Molecule to Inhibit GPR-84 for Chronic Pain-Drug Profile 243

Small Molecule to Inhibit mPGES-1 for Chronic Pain-Drug Profile 244

Small Molecule to Inhibit P2Y14 for Chronic Pain-Drug Profile 245

Small Molecule to Modulate Ion Channel for Chronic Pain-Drug Profile 246

Small Molecules to Activate KCNQ Channels for Chronic Pain and CNS disorder-Drug Profile 247

Small Molecules to Activate Mu Opioid Receptor for Chronic Pain-Drug Profile 248

Small Molecules to Agonize NOP for Pain-Drug Profile 249

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS-Drug Profile 250

Small Molecules to Antagonize P2X3 for Chronic Pain-Drug Profile 251

Small Molecules to Antagonize Tyrosine Kinase Receptor A for Chronic Pain-Drug Profile 252

Small Molecules to Block Cav2.2 Channel for Chronic Pain-Drug Profile 253

Small Molecules to Block Cav2.2 Channel for Chronic Pain-Drug Profile 254

Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain-Drug Profile 255

Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain-Drug Profile 256

Small Molecules to Block Nav1.7 for Pain-Drug Profile 257

Small Molecules to Block TRPA1 and TRPV1 for CNS-Drug Profile 258

Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain-Drug Profile 259

SND-121 Prodrug-Drug Profile 260

sufentanil citrate-Drug Profile 261

Synthetic Peptide to Inhibit CRMP-2 Protein for Pain-Drug Profile 263

tapentadol hydrochloride-Drug Profile 264

tramadol hydrochloride SR-Drug Profile 265

TROX-1-Drug Profile 266

TRV-734-Drug Profile 267

U-2902-Drug Profile 268

UMB-425-Drug Profile 269

V-116517-Drug Profile 270

VLNX-4975-Drug Profile 271

YYC-301-Drug Profile 272

ZEP-3-Drug Profile 273

ZYN-001-Drug Profile 275

Chronic Pain-Recent Pipeline Updates 276

Chronic Pain-Dormant Projects 315

Chronic Pain-Discontinued Products 322

Chronic Pain-Product Development Milestones 324

Featured News & Press Releases 324

Appendix 333

Methodology 333

Coverage 333

Secondary Research 333

Primary Research 333

Expert Panel Validation 333

Contact Us 333

Disclaimer 334

List of Tables

Number of Products under Development for Chronic Pain, H1 2015 23

Number of Products under Development for Chronic Pain-Comparative Analysis, H1 2015 24

Number of Products under Development by Companies, H1 2015 26

Number of Products under Development by Companies, H1 2015 (Contd..1) 27

Number of Products under Development by Companies, H1 2015 (Contd..2) 28

Number of Products under Development by Companies, H1 2015 (Contd..3) 29

Number of Products under Development by Companies, H1 2015 (Contd..4) 30

Number of Products under Development by Companies, H1 2015 (Contd..5) 31

Number of Products under Investigation by Universities/Institutes, H1 2015 32

Comparative Analysis by Late Stage Development, H1 2015 33

Comparative Analysis by Clinical Stage Development, H1 2015 34

Comparative Analysis by Early Stage Development, H1 2015 35

Comparative Analysis by Unknown Stage Development, H1 2015 36

Products under Development by Companies, H1 2015 37

Products under Development by Companies, H1 2015 (Contd..1) 38

Products under Development by Companies, H1 2015 (Contd..2) 39

Products under Development by Companies, H1 2015 (Contd..3) 40

Products under Development by Companies, H1 2015 (Contd..4) 41

Products under Development by Companies, H1 2015 (Contd..5) 42

Products under Development by Companies, H1 2015 (Contd..6) 43

Products under Development by Companies, H1 2015 (Contd..7) 44

Products under Investigation by Universities/Institutes, H1 2015 45

Chronic Pain-Pipeline by AbbVie Inc., H1 2015 46

Chronic Pain-Pipeline by Acadia Pharmaceuticals Inc., H1 2015 47

Chronic Pain-Pipeline by Adynxx, Inc., H1 2015 48

Chronic Pain-Pipeline by Akron Molecules AG, H1 2015 49

Chronic Pain-Pipeline by Allergan, Inc., H1 2015 50

Chronic Pain-Pipeline by arGEN-X BV, H1 2015 51

Chronic Pain-Pipeline by Astellas Pharma Inc., H1 2015 52

Chronic Pain-Pipeline by Astraea Therapeutics, LLC, H1 2015 53

Chronic Pain-Pipeline by AstraZeneca PLC, H1 2015 54

Chronic Pain-Pipeline by BCN Peptides, S.A., H1 2015 55

Chronic Pain-Pipeline by BioDelivery Sciences International, Inc., H1 2015 56

Chronic Pain-Pipeline by Bionomics Limited, H1 2015 57

Chronic Pain-Pipeline by Cara Therapeutics, Inc., H1 2015 58

Chronic Pain-Pipeline by ChironWells GmbH, H1 2015 59

Chronic Pain-Pipeline by Chromocell Corporation, H1 2015 60

Chronic Pain-Pipeline by Collegium Pharmaceutical, Inc., H1 2015 61

Chronic Pain-Pipeline by CoLucid Pharmaceuticals, Inc., H1 2015 62

Chronic Pain-Pipeline by Convergence Pharmaceuticals Ltd., H1 2015 63

Chronic Pain-Pipeline by Creabilis SA, H1 2015 64

Chronic Pain-Pipeline by Cytogel Pharma, LLC, H1 2015 65

Chronic Pain-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 66

Chronic Pain-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 67

Chronic Pain-Pipeline by Dompe Farmaceutici S.p.A., H1 2015 68

Chronic Pain-Pipeline by DURECT Corporation, H1 2015 69

Chronic Pain-Pipeline by Egalet Corporation, H1 2015 70

Chronic Pain-Pipeline by Eli Lilly and Company, H1 2015 71

Chronic Pain-Pipeline by Endo Pharmaceuticals Inc., H1 2015 72

Chronic Pain-Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 73

Chronic Pain-Pipeline by Grunenthal GmbH, H1 2015 74

Chronic Pain-Pipeline by Johnson & Johnson, H1 2015 75

Chronic Pain-Pipeline by Kareus Therapeutics, SA, H1 2015 76

Chronic Pain-Pipeline by Kineta, Inc., H1 2015 77

Chronic Pain-Pipeline by Kymab Limited, H1 2015 78

Chronic Pain-Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2015 79

Chronic Pain-Pipeline by Lohocla Research Corporation, H1 2015 80

Chronic Pain-Pipeline by Merck & Co., Inc., H1 2015 81

Chronic Pain-Pipeline by Mertiva AB, H1 2015 82

Chronic Pain-Pipeline by Mesoblast Limited, H1 2015 83

Chronic Pain-Pipeline by Moberg Pharma AB, H1 2015 84

Chronic Pain-Pipeline by Mundipharma International Limited, H1 2015 85

Chronic Pain-Pipeline by Nanomerics Ltd, H1 2015 86

Chronic Pain-Pipeline by Nektar Therapeutics, H1 2015 87

Chronic Pain-Pipeline by Neura Therapeutik, LLC, H1 2015 88

Chronic Pain-Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 89

Chronic Pain-Pipeline by Orion Oyj, H1 2015 90

Chronic Pain-Pipeline by Pain Therapeutics, Inc., H1 2015 91

Chronic Pain-Pipeline by Pfizer Inc., H1 2015 92

Chronic Pain-Pipeline by Phosphagenics Limited, H1 2015 93

Chronic Pain-Pipeline by Purdue Pharma L.P., H1 2015 94

Chronic Pain-Pipeline by Relmada Therapeutics, Inc., H1 2015 95

Chronic Pain-Pipeline by Rottapharm SpA, H1 2015 96

Chronic Pain-Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 97

Chronic Pain-Pipeline by Sea4Us, H1 2015 98

Chronic Pain-Pipeline by Shionogi & Co., Ltd., H1 2015 99

Chronic Pain-Pipeline by Signature Therapeutics, Inc, H1 2015 100

Chronic Pain-Pipeline by Snowdon Inc., H1 2015 101

Chronic Pain-Pipeline by Syntrix Biosystems, Inc., H1 2015 102

Chronic Pain-Pipeline by Teikoku Pharma USA, Inc., H1 2015 103

Chronic Pain-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 104

Chronic Pain-Pipeline by Trevena, Inc., H1 2015 105

Chronic Pain-Pipeline by UMeWorld Limited, H1 2015 106

Chronic Pain-Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 107

Assessment by Monotherapy Products, H1 2015 108

Assessment by Combination Products, H1 2015 109

Number of Products by Stage and Target, H1 2015 111

Number of Products by Stage and Mechanism of Action, H1 2015 115

Number of Products by Stage and Route of Administration, H1 2015 119

Number of Products by Stage and Molecule Type, H1 2015 121

Chronic Pain Therapeutics-Recent Pipeline Updates, H1 2015 286

Chronic Pain-Dormant Projects, H1 2015 325

Chronic Pain-Dormant Projects (Contd..1), H1 2015 326

Chronic Pain-Dormant Projects (Contd..2), H1 2015 327

Chronic Pain-Dormant Projects (Contd..3), H1 2015 328

Chronic Pain-Dormant Projects (Contd..4), H1 2015 329

Chronic Pain-Dormant Projects (Contd..5), H1 2015 330

Chronic Pain-Dormant Projects (Contd..6), H1 2015 331

Chronic Pain-Discontinued Products, H1 2015 332

Chronic Pain-Discontinued Products (Contd..1), H1 2015 333

List of Figures

Number of Products under Development for Chronic Pain, H1 2015 23

Number of Products under Development for Chronic Pain-Comparative Analysis, H1 2015 24

Number of Products under Development by Companies, H1 2015 25

Number of Products under Investigation by Universities/Institutes, H1 2015 32

Comparative Analysis by Late Stage Development, H1 2015 33

Comparative Analysis by Clinical Stage Development, H1 2015 34

Comparative Analysis by Early Stage Products, H1 2015 35

Assessment by Monotherapy Products, H1 2015 108

Assessment by Combination Products, H1 2015 109

Number of Products by Top 10 Targets, H1 2015 110

Number of Products by Stage and Top 10 Targets, H1 2015 110

Number of Products by Top 10 Mechanism of Actions, H1 2015 114

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 114

Number of Products by Top 10 Routes of Administration, H1 2015 118

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 119

Number of Products by Top 10 Molecule Types, H1 2015 120

Number of Products by Stage and Top 10 Molecule Types, H1 2015 120

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Acadia Pharmaceuticals Inc.

Adynxx, Inc.

Akron Molecules AG

Allergan, Inc.

arGEN-X BV

Astellas Pharma Inc.

Astraea Therapeutics, LLC

AstraZeneca PLC

BCN Peptides, S.A.

BioDelivery Sciences International, Inc.

Bionomics Limited

Cara Therapeutics, Inc.

ChironWells GmbH

Chromocell Corporation

Collegium Pharmaceutical, Inc.

CoLucid Pharmaceuticals, Inc.

Convergence Pharmaceuticals Ltd.

Creabilis SA

Cytogel Pharma, LLC

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Dompe Farmaceutici S.p.A.

DURECT Corporation

Egalet Corporation

Eli Lilly and Company

Endo Pharmaceuticals Inc.

Glenmark Pharmaceuticals Ltd.

Grunenthal GmbH

Johnson & Johnson

Kareus Therapeutics, SA

Kineta, Inc.

Kymab Limited

Laboratorios Del Dr. Esteve S.A.

Lohocla Research Corporation

Merck & Co., Inc.

Mertiva AB

Mesoblast Limited

Moberg Pharma AB

Mundipharma International Limited

Nanomerics Ltd

Nektar Therapeutics

Neura Therapeutik, LLC

Nippon Shinyaku Co., Ltd.

Orion Oyj

Pain Therapeutics, Inc.

Pfizer Inc.

Phosphagenics Limited

Purdue Pharma L.P.

Relmada Therapeutics, Inc.

Rottapharm SpA

Santen Pharmaceutical Co., Ltd.

Sea4Us

Shionogi & Co., Ltd.

Signature Therapeutics, Inc

Snowdon Inc.

Syntrix Biosystems, Inc.

Teikoku Pharma USA, Inc.

Teva Pharmaceutical Industries Limited

Trevena, Inc.

UMeWorld Limited

Zynerba Pharmaceuticals, Inc.

Chronic Pain Therapeutic Products under Development, Key Players in Chronic Pain Therapeutics, Chronic Pain Pipeline Overview, Chronic Pain Pipeline, Chronic Pain Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com